U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07564401) titled 'A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy' on April 27.
Brief Summary: This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.
Study Start Date: May 14
Study Type: INTERVENTIONAL
Condition:
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Intervention:
DRUG: DJI136
DLL3 targeted CAR-T therapy administered by intravenous (i.v.) infusion.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Discla...